Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

Immunicum AB. (12/29/17). "Press Release: Immunicum AB (publ) Announces the Outcome of the Rights Issue [Not for US, AU, CA, et al.]".

Organisations Organisation Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)
  Group Immunicum (Group)
  Organisation 2 Nasdaq Stockholm
  Group Nasdaq OMX (Group)
Products Product ilixadencel
  Product 2 investment banking
Index term Index term Immunicum–SEVERAL: investment, 201711–201712 capital increase SEK200m net SEK168m with 25m new shares at SEK8/share
Persons Person de Sousa, Carlos (Immunicum 201610– CEO before Zealand Pharma + Nycomed/Takeda + Pfizer + Novartis + BBB Therapeutics)
  Person 2 Schweitzer, Gretchen (Trophic Comunications 201801 before MacDougall European Office)
     


   
Record changed: 2018-10-20

Advertisement

Picture EBD Group Global Partnering Four Events One Price 650x80

More documents for Immunicum (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Berlin Partner Network in German Capital Region 650x80px




» top